Search results
Showing 451 to 465 of 2576 results for methods
Awaiting development Reference number: GID-TA11202 Expected publication date: TBC
In development Reference number: GID-TA11803 Expected publication date: TBC
In development Reference number: GID-TA11850 Expected publication date: 03 September 2026
In development Reference number: GID-TA11229 Expected publication date: TBC
Awaiting development Reference number: GID-TA11040 Expected publication date: TBC
Awaiting development Reference number: GID-TA11876 Expected publication date: TBC
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
Awaiting development Reference number: GID-TA11784 Expected publication date: 21 July 2027
Awaiting development Reference number: GID-TA11748 Expected publication date: TBC
Awaiting development Reference number: GID-TA11769 Expected publication date: TBC
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]
Awaiting development Reference number: GID-TA10993 Expected publication date: TBC
Awaiting development Reference number: GID-TA11469 Expected publication date: TBC
This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]
Awaiting development Reference number: GID-TA11467 Expected publication date: TBC
Awaiting development Reference number: GID-TA11490 Expected publication date: TBC